Mesa Laboratories (NASDAQ:MLAB) Hits New 52-Week High – Here’s What Happened

Posted by Brenda Bartman on Sep 22nd, 2026

Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $133.55 and last traded at $133.6950, with a volume of 52487 shares trading hands. The stock had previously closed at $131.87.

Wall Street Analysts Forecast Growth

Several brokerages have commented on MLAB. Weiss Ratings upgraded shares of Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Wells Fargo & Company upped their target price on Mesa Laboratories from $94.00 to $110.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Finally, Wall Street Zen lowered Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 15th. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $110.00.

Get Our Latest Research Report on MLAB

Mesa Laboratories Trading Up 1.9%

The firm’s 50 day moving average price is $113.36 and its 200-day moving average price is $102.40. The stock has a market cap of $752.30 million, a P/E ratio of 159.95 and a beta of 0.97. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.79 and a quick ratio of 1.32.

Mesa Laboratories (NASDAQ:MLAB – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share for the quarter. The company had revenue of $60.14 million during the quarter. Mesa Laboratories had a net margin of 1.92% and a return on equity of 22.72%.

Mesa Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st were issued a $0.16 dividend. The ex-dividend date of this dividend was Monday, August 31st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.5%. Mesa Laboratories’s dividend payout ratio (DPR) is presently 76.19%.

Insider Transactions at Mesa Laboratories

In other Mesa Laboratories news, Director R Tripeny acquired 900 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were bought at an average cost of $113.69 per share, with a total value of $102,321.00. Following the completion of the transaction, the director directly owned 6,298 shares of the company’s stock, valued at approximately $716,019.62. This represents a 16.67% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Siddhartha Kadia acquired 7,093 shares of Mesa Laboratories stock in a transaction that occurred on Thursday, August 13th. The stock was acquired at an average price of $112.80 per share, with a total value of $800,090.40. Following the completion of the acquisition, the chief executive officer directly owned 7,093 shares in the company, valued at $800,090.40. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 2.80% of the company’s stock.

Institutional Trading of Mesa Laboratories

A number of institutional investors have recently made changes to their positions in MLAB. Engineers Gate Manager LP raised its holdings in shares of Mesa Laboratories by 291.2% during the second quarter. Engineers Gate Manager LP now owns 14,731 shares of the medical instruments supplier’s stock valued at $1,466,000 after purchasing an additional 10,965 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in Mesa Laboratories during the second quarter valued at approximately $87,000. Baird Financial Group Inc. purchased a new stake in Mesa Laboratories in the second quarter worth approximately $231,000. Allworth Financial LP grew its position in Mesa Laboratories by 110.0% in the 2nd quarter. Allworth Financial LP now owns 523 shares of the medical instruments supplier’s stock worth $52,000 after purchasing an additional 274 shares during the period. Finally, Corient Private Wealth LP purchased a new stake in Mesa Laboratories during the 2nd quarter valued at $241,000. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Company Profile

(Get Free Report)

Mesa Laboratories, Inc develops, manufactures, and sells quality-control products and services used in healthcare, pharmaceutical, industrial, and other regulated environments. The company’s offerings are designed to help customers monitor processes, verify performance, and maintain compliance with applicable quality and safety requirements.

Mesa Laboratories’ products include biological indicators and other sterilization-assurance products used to evaluate sterilization processes in hospitals, dental practices, laboratories, and pharmaceutical manufacturing.